Efficient primer group, kit and method for detecting acinetobacter baumannii

By providing efficient primer sets and polymerase chain reaction technology, the cost and complex problems of Acinetobacter baudis detection method are solved, and more efficient and sensitive detection is achieved, which is suitable for clinical applications.

CN119040489APending Publication Date: 2024-11-29SUZHOU HAIMIAO BIOTECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410070037.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-01-18
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The existing detection methods for Acinetobacter bauble have problems such as expensive and complex operation, and are difficult to promote and apply in clinical laboratories.

Method used

Provides an efficient primer set, including forward primer sequence, reverse primer sequence and probe sequence, combined with polymerase chain reaction (PCR) technology, and is detected by qPCR amplification method, which optimizes the A. B. baumannii Clinical screening and scientific research.

Benefits of technology

The primer sets with higher amplification efficiency, higher sensitivity and lower limit detection were screened, which simplified the detection process, reduced costs, and was suitable for clinical applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119040489A_ABST
    Figure CN119040489A_ABST
Patent Text Reader

Abstract

The invention discloses a high-efficiency primer group, a kit and a method for detecting acinetobacter baumannii, the high-efficiency primer group for detecting the acinetobacter baumannii comprises a forward primer sequence SEQ ID NO.5 TCGCAACGGTTGTTGTAGTTG, a reverse primer sequence SEQ ID NO.6 GTACACCCGTCAATACGCCTAAT and a probe sequence SEQ ID NO.7 AGCTACACAATCTAG, the forward primer sequence SEQ ID NO.6 is TCGCAACGGTTGTTGTAGTTG, the reverse primer sequence SEQ ID NO.6 is GTACACCCGTCAATACGCCTAAT is GTACACCCGATACGCTAG, the reverse primer sequence SEQ ID NO.6 is The method comprises the following steps: carrying out qPCR by adopting the screened primer group; the efficient primer group, the kit and the method for detecting the acinetobacter baumannii, provided by the invention, have important significance and application value for optimizing clinical screening or scientific research of the acinetobacter baumannii.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of medical technology, and in particular to a high-efficiency primer set, a kit and a method for detecting Acinetobacter bubauii. Background Art

[0002] Acinetobacter baumannii, also known as Acinetobacter baumannii, usually appears in water and soil. Since this bacterium generally only causes illness in people with reduced immune function, it is often considered a non-pathogenic bacterium or a conditional pathogen and its importance is ignored. In recent years, lung infections caused by Acinetobacter baumannii have gradually increased, often causing lung infections in hospitalized patients and those with significantly reduced resistance. In particular, chronic obstructive pulmonary disease, decreased respiratory defense function, weakened bronchial clearance ability, or bronchial lung cancer leading to bronchial obstruction are prone to secondary infection with Acinetobacter baumannii.

[0003] At present, although there are many molecular biological methods for the identification of Acinetobacter baumannii, some methods are expensive, some methods are complicated to operate, and it is difficult to promote and apply them in clinical laboratories. The detection method based on polymerase chain reaction is low in cost, simple to operate, and easy to promote. Summary of the invention

[0004] The present invention provides an efficient primer set, a kit and a method for detecting Acinetobacter baumannii, which have important significance and application value for optimizing clinical screening or scientific research of Acinetobacter baumannii.

[0005] To achieve this object, the present invention provides the following technical solutions:

[0006] The first aspect of the present invention provides an efficient primer set for detecting Acinetobacter baumannii, comprising a forward primer sequence SEQ ID NO.5, a reverse primer sequence SEQ ID NO.6 and a probe sequence SEQ ID NO.7;

[0007] F2 (SEQ ID NO.5): TCGCAACGGGTTGTTGTAGTTG;

[0008] R2 (SEQ ID NO.6): GTACACCCGTCAATACGCCTAAT;

[0009] P2 (SEQ ID NO. 7): AGCTACTCACAATCTAG.

[0010] Preferably, in the reaction system, the concentration of the forward primer sequence, the reverse primer sequence or the probe sequence is 0.1-0.25 μmol / L.

[0011] The second aspect of the present invention provides a kit for detecting Acinetobacter baumannii, comprising a forward primer sequence of SEQ ID NO.5, a reverse primer sequence of SEQ ID NO.6 and a probe sequence of SEQ ID NO.7.

[0012] Preferably, it also includes 5*buffer, Mg 2+ , dNTP, Taq enzyme and reverse transcription system.

[0013] Preferably, the initial concentrations of the forward primer sequence SEQ ID NO.5, the reverse primer sequence SEQ ID NO.6 and the probe sequence SEQ ID NO.7 are all 10 uM.

[0014] A third aspect of the present invention provides a method for detecting Acinetobacter baumannii for non-diagnostic purposes, comprising the following steps:

[0015] S1. Extract total DNA from samples;

[0016] S2, add 5*buffer, Mg 2+ , dNTP, Taq enzyme, reverse transcription system, water, forward primer, reverse primer and probe, wherein the concentrations of the forward primer sequence SEQ ID NO.5, the reverse primer sequence SEQ ID NO.6 and the probe sequence SEQ ID NO.7 are all 10uM;

[0017] S3. Perform qPCR amplification on the reaction system.

[0018] Preferably, in step S2, the final concentration of the forward primer sequence, the reverse primer sequence or the probe sequence is 0.1-0.25 μmol / L.

[0019] Preferably, in step S3, the reaction conditions for qPCR amplification are: heated lid 100-105°C, preheated 90-95°C, denatured 90-95°C, annealed 55-60°C, extended 70-72°C, and denatured, annealed and extended 40 times in total.

[0020] Preferably, the reaction system in step S2 is 5*buffer 5uL, Mg 2+ 1.25uL, dNTP 0.5uL, F primer (10uM) 0.35uL, R primer (10uM) 0.35uL, probe (10uM) 0.3uL, Taq enzyme 0.35uL, reverse transcription system 1uL, H2O 10.25uL, sample 5uL.

[0021] Preferably, in step S3, the reaction conditions for qPCR amplification are:

[0022]

[0023]

[0024] Compared with the prior art, the beneficial effects and significant progress of the present invention are: the present invention screened a large number of primer sets for detecting Acinetobacter bubbaumii, and finally screened out a primer set with an amplification efficiency of 101.6%, a more standard amplification curve, higher sensitivity and a low limit of detection. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] In order to more clearly illustrate the technical solution of the present invention, the following briefly introduces the drawings required for use in the embodiments of the present invention.

[0026] Obviously, the drawings described below are only drawings of some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work, but these other drawings also belong to the drawings required for use in the embodiments of the present invention.

[0027] Figure 1 is the amplification curve of the primer probe set 1 of Example 2 of the present invention for the Acinetobacter baumannii sequence;

[0028] Figure 2 is the amplification standard curve of the primer probe set 1 of Example 2 of the present invention for the sequence of Acinetobacter baumannii;

[0029] Figure 3 is the amplification curve of the primer probe set 2 of Example 2 of the present invention for the Acinetobacter baumannii sequence;

[0030] Figure 4 is the amplification standard curve of the primer probe set 2 of Example 2 of the present invention for the Acinetobacter baumannii sequence;

[0031] Figure 5 is an amplification curve of the precision detection of the primer probe set 1 of Example 3 of the present invention;

[0032] Figure 6 is the internal standard amplification curve of the precision detection of the primer probe set 1 of Example 3 of the present invention;

[0033] FIG7 is an amplification curve of the precision detection of the primer probe set 2 of Example 3 of the present invention;

[0034] FIG8 is an internal standard amplification curve of the precision detection of primer probe set 2 of Example 3 of the present invention;

[0035] Fig. 9 is the minimum detection amplification curve of the primer probe set 1 of Example 4 of the present invention;

[0036] Fig.10 is a minimum detection internal standard amplification curve of the primer probe set 1 of Example 4 of the present invention;

[0037] Fig.11 is the minimum detection amplification curve of the primer probe set 2 of Example 4 of the present invention;

[0038] Fig.12 This is the minimum detection internal standard amplification curve of the primer probe set 2 of Example 4 of the present invention;

[0039] Fig.13 This is a clinical sample detection amplification curve diagram of the primer probe set 1 of Example 4 of the present invention;

[0040] Fig.14 is an internal standard amplification curve of a clinical sample of the primer probe set 1 of Example 4 of the present invention;

[0041] Fig.15 This is a clinical sample detection amplification curve diagram of the primer probe set 2 of Example 4 of the present invention;

[0042] Fig.16 This is an internal standard amplification curve of the clinical sample of the primer probe set 2 of Example 4 of the present invention. DETAILED DESCRIPTION

[0043] In order to make the purpose, technical solution, beneficial effects and significant improvements of the embodiments of the present invention more clear, the technical solution in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings provided in the embodiments of the present invention.

[0044] Obviously, all the described embodiments are only partial embodiments of the present invention, rather than all the embodiments; based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making any creative work are within the scope of protection of the present invention.

[0045] For those skilled in the art, the specific meanings of the above terms in the present invention can be understood according to specific circumstances.

[0046] The term "forward primer sequence" in the present invention refers to a primer located upstream of a double-stranded DNA. When used for sequencing, the sequence of the forward strand of the DNA is read from the 5' to the 3' direction.

[0047] The term "reverse primer sequence" in the present invention means that the reverse primer (downstream primer) is extended along the positive strand. In vitro amplification of DNA, the double helix is ​​partially or completely opened, there is no Okazaki fragment, and it will not be extended in segments. In theory, both the forward and reverse primers are extended continuously, which is different from the self-replication of DNA in vivo.

[0048] The term "probe" in the present invention refers to: a nucleic acid sequence (DNA or RNA) with a detection label and a known sequence that is complementary to the target gene. The gene probe binds to the target gene through molecular hybridization to generate a hybridization signal, which can display the target gene from the vast genome. According to the hybridization principle, the nucleic acid sequence used as a probe must meet at least the following two conditions: ① It should be single-stranded. If it is double-stranded, it must be denatured first. ② It should carry a label that is easily detected. It can include the entire gene or just a part of the gene; it can be DNA itself or RNA transcribed from it.

[0049] The term "qPCR" in the present invention refers to: Real-time Quantitative PCR Detecting System, that is, real-time fluorescence quantitative nucleic acid amplification detection system, also called real-time quantitative gene amplification fluorescence detection system.

[0050] It should also be noted that the following specific embodiments may be combined with each other, and the same or similar concepts or processes therein may not be repeated in some embodiments.

[0051] The technical solution of the present invention is described in detail below with specific embodiments.

[0052] Example 1 Determining the detection sequence range and primer design

[0053] 1.1. Determine the detection sequence range

[0054] The detection sequence range of the present invention: the common conservative gene qacE△1-sul1 sequence for detecting Acinetobacter baumannii, sequence number SEQ ID NO.1:

[0055] CCGAGTAATAAATTTAAGGAATGTAAAGGTCAAGGTATTGCCAATATTGCCTCGGGTTTTATGGGTGGGATGGCTGGATGTGCCATGATTGGGCAATCAATGATTAATGTTAAATCAGGTGGTCGCACACGCTTATCTACATTATGCGCAGGCATATTCTTGCTGATTTTAGTAGTATTTTTAAGTGATTGGTTGAAAGT TATTCCTATGGCTGCTTGTTGCTGTCATGATTATGGTATCAATAAGTACTTTTGAGTGGCGTTCACTTACCCAATTTAAAACTAATCCTAAAAGTAGCAATACCGTTATGATCGCAACGGTTGTTGTAGTTGTAGCTACTCACAATCTAGCATTAGGCGTATTGACGGGTGTACTACTTTCCGCGCTTTTCTTAGCCA.

[0056] 1.2 Primer design and screening

[0057] The present invention designs multiple sets of primer probe sets for the sequence selection in step 1.1, and conducts verification experiments. Due to space limitations, only two sets of primer probe sets with better verification results are disclosed in the following examples.

[0058] Primer probe set 1:

[0059] F1 (SEQ ID NO.2): GCCAATATTGCCTCGGGTTT;

[0060] R1 (SEQ ID NO.3): TTGCCCAATCATGGCACAT;

[0061] P1 (SEQ ID NO. 4):ATGGGTGGGATGGCT.

[0062] Primer probe set 2:

[0063] F2 (SEQ ID NO.5): TCGCAACGGGTTGTTGTAGTTG;

[0064] R2 (SEQ ID NO.6): GTACACCCGTCAATACGCCTAAT;

[0065] P2 (SEQ ID NO. 7): AGCTACTCACAATCTAG.

[0066] Example 2 Difference in amplification efficiency between two sets of primer probes under the same reaction system concentration and other conditions

[0067] Experimental methods

[0068] The detection method of this embodiment is qPCR, and the reaction system is shown in Table 1 below.

[0069] Table 1: Amplification efficiency comparison experimental reaction system table

[0070]

[0071]

[0072] Primer probe set 1 and primer probe set 2 were used to perform qPCR amplification on the Acinetobacter baumannii sequence, and the amplification curve and amplification standard curve were detected, and the amplification effect was statistically analyzed.

[0073] Experimental Results

[0074] As shown in Table 2, it is a graph showing the amplification efficiency results of primer probe set 1 and primer probe set 2.

[0075] Table 2 Amplification efficiency comparison test results

[0076]

[0077] like Figure 1 , 2 Shown are the amplification curve and amplification standard curve of qPCR amplification of Acinetobacter baumannii sequence by primer probe set 1.

[0078] like Figure 3 , 4 Shown are the amplification curve and amplification standard curve of qPCR amplification of Acinetobacter baumannii sequence by primer probe set 2.

[0079] From the results of the amplification standard curve experiment, we know that under the same conditions, the amplification efficiency of primer probe set 2 is 101.6%, and the amplification efficiency of primer probe set 1 is 95.56%. The amplification efficiency of primer probe set 2 is higher than that of primer probe set 1. Therefore, under this reaction condition, primer probe set 2 has better amplification efficiency and is more suitable for clinical testing.

[0080] Example 3 Precision detection of two sets of primer probes

[0081] Experimental methods

[0082] The detection method of this embodiment is qPCR, and the reaction system is shown in Table 3 below.

[0083] Table 3 Reaction system of qCPR reaction for precision detection

[0084]

[0085]

[0086] Primer probe set 1 and primer probe set 2 were used to perform qPCR amplification on the Acinetobacter baumannii sequence, and the amplification curve was precisely detected and the amplification results were statistically analyzed.

[0087] Experimental Results

[0088] like Figure 5 , 6 Shown is the amplification curve of qPCR amplification of Acinetobacter baumannii sequence by primer probe set 1.

[0089] like Figure 7 , 8 Shown is the amplification curve of qPCR amplification of Acinetobacter baumannii sequence by primer probe set 2.

[0090] As shown in Figure 4, it is the qPCR reaction result table of precision detection.

[0091] Table 4 qPCR reaction results of precision detection

[0092]

[0093] From the experimental results of precision detection, the detection CV value of primer probe set 2 is 0.2469%, and the detection CV value of primer probe set 1 is 0.5093%. Compared with primer probe set 1, primer probe set 2 is more stable and more suitable for clinical detection.

[0094] Example 4 Minimum detection limit of two sets of primer probes

[0095] Experimental methods

[0096] The detection method of this embodiment is qPCR, and the reaction system is shown in Table 5 below.

[0097] Table 5 Reaction system of qCPR reaction with minimum detection limit

[0098]

[0099] Primer probe set 1 and primer probe set 2 were used to perform qPCR amplification on the Acinetobacter baumannii sequence, and a minimum limit detection amplification curve was performed and the amplification results were statistically analyzed.

[0100] Experimental Results

[0101] like Fig. 9 , 10 Shown are the amplification curve and internal standard channel result diagram of qPCR amplification of Acinetobacter baumannii sequence by primer probe set 1.

[0102] like Fig.11 , 12 Shown are the amplification curve and internal standard channel result diagram of qPCR amplification of Acinetobacter baumannii sequence by primer probe set 2.

[0103] Table 6 shows the qPCR reaction results for the minimum detection limit.

[0104] Table 6 qPCR reaction results of minimum detection limit

[0105]

[0106]

[0107] From the experimental results of the minimum detection limit, it can be seen that primer probe set 2 is partially detected or not detected, and primer probe set 1 is not detected at all. For extremely low concentration sample conditions, primer probe set 2 has better detection results.

[0108] Example 5 qPCR test results of clinical samples

[0109] Experimental methods

[0110] The detection method of this embodiment is qPCR, and the reaction system is shown in Table 7 below.

[0111] Table 7 Clinical sample detection reaction system

[0112]

[0113] Primer probe set 1 and primer probe set 2 were used to perform qPCR amplification on the Acinetobacter baumannii sequence, and the amplification curves of clinical samples were tested and the amplification results were statistically analyzed.

[0114] Experimental Results

[0115] like Fig.13 , 14 Shown are the amplification curve and internal standard channel result diagram of qPCR amplification of Acinetobacter baumannii sequence by primer probe set 1.

[0116] like Fig.15 , 16 Shown are the amplification curve and internal standard channel result diagram of qPCR amplification of Acinetobacter baumannii sequence by primer probe set 2.

[0117] As shown in Table 8, this is the clinical sample test results table.

[0118] As shown in Table 9, this is the internal standard results table for clinical sample testing.

[0119] Table 8 Clinical sample test results

[0120]

[0121] Table 9 Clinical sample detection internal standard results

[0122]

[0123] The detection results of primer probe set 1 and primer probe set 2 for clinical samples were both accurate, and the detection efficiency of the two sets of primer probes was comparable. However, considering the minimum detection limit, primer probe set 2 was more advantageous.

[0124] In the description of the above manual:

[0125] The descriptions of the terms "this embodiment", "an embodiment of the present invention", "as shown in...", "further", "a further improved technical sub-scheme", etc., mean that the specific features, structures, materials or characteristics described in the embodiment or example are included in at least one embodiment or example of the present invention; in this specification, the schematic expressions of the above terms are not necessarily for the same embodiment or example, and the specific features, structures, materials or characteristics described may be combined or combined in a suitable manner in any one or more embodiments or examples; in addition, a person of ordinary skill in the art may combine or combine the different embodiments or examples and the features of the different embodiments or examples described in this specification without causing any contradiction.

[0126] Finally, it should be noted that:

[0127] The above embodiments are only used to illustrate the technical solutions of the present invention, but not to limit them.

[0128] Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some or all of the technical features therein, and these modifications or replacements do not make the essence of the corresponding technical solutions deviate from the scope of the technical solutions of the embodiments of the present invention. The non-essential improvements, adjustments or replacements made by those skilled in the art based on the contents of this specification are all within the scope of protection required by the present invention.

Claims

1. An efficient primer set for detecting Acinetobacter baumannii, It is characterized in that It includes a forward primer sequence of SEQ ID NO.5, a reverse primer sequence of SEQ ID NO.6 and a probe sequence of SEQ ID NO.

7.

2. The highly effective primer set for detecting Acinetobacter baumannii according to claim 1, It is characterized in that In the reaction system, the concentration of the forward primer sequence, the reverse primer sequence or the probe sequence is 0.1-0.25 μmol / L.

3. A kit for detecting Acinetobacter baumannii, It is characterized in that It includes a forward primer sequence of SEQ ID NO.5, a reverse primer sequence of SEQ ID NO.6 and a probe sequence of SEQ ID NO.

7.

4. A kit for detecting Acinetobacter baumannii as claimed in claim 3, It is characterized in that Also includes 5*buffer, Mg 2+ , dNTP, Taq enzyme and reverse transcription system.

5. A kit for detecting Acinetobacter baumannii as claimed in claim 3, It is characterized in that The initial concentrations of the forward primer sequence SEQ ID NO.5, the reverse primer sequence SEQ ID NO.6 and the probe sequence SEQ ID NO.7 were all 10 uM.

6. A method for detecting Acinetobacter baumannii for non-diagnostic purposes, It is characterized in that The following steps are involved: S1. Extract total DNA from samples; S2, add 5*buffer, Mg 2+ , dNTP, Taq enzyme, reverse transcription system, water, forward primer, reverse primer and probe, wherein the concentrations of the forward primer sequence SEQ ID NO.5, the reverse primer sequence SEQ ID NO.6 and the probe sequence SEQ ID NO.7 are all 10uM; S3. Perform qPCR amplification on the reaction system.

7. A method for detecting Acinetobacter baumannii for non-diagnostic purposes as claimed in claim 6, It is characterized in that In step S2, the final concentration of the forward primer sequence, the reverse primer sequence or the probe sequence is 0.1-0.25 μmol / L.

8. A method for detecting Acinetobacter baumannii for non-diagnostic purposes as claimed in claim 6, It is characterized in that In step S3, the reaction conditions for qPCR amplification are: heated lid 100-105°C, preheated 90-95°C, denatured 90-95°C, annealed 55-60°C, extended 70-72°C, and denatured, annealed and extended 40 times in total.